FDA ApprovedUnited States
First FDA-Approved Treatment for Adults With Recurrent Respiratory Papillomatosis
Papzimeos (zopapogene imadenovec-drba) — four subcutaneous shots over 12 weeks for adults with recurrent respiratory papillomatosis
FDA traditional/full approval on 14 August 2025 for Papzimeos (zopapogene imadenovec-drba) suspension — a non-replicating adenoviral vector immunotherapy given…
This is for adults living with recurrent respiratory papillomatosis who still need repeated airway surgeries and may be candidates for labelled US Papzimeos…